Li Xinghai - Department of Biomedical Engineering, Duke University

基本信息

浏览量：20

职业迁徙

个人简介

Ph.D. in School of Information Engineering, Henan University of Science and Technology. His research interests include machine learning, knowledge transfer and computer vision.

研究兴趣

论文共 56 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract LB179: Identification of the Highly Potent and Orally Available ER-targeting PROTAC Degrader HP568 for the Treatment of Breast Cancer

Wu Du, Zhilin Tu, Dekun Qin, Haibo Li, Jingyi Duan, Shijuan Liu, Meng Zhang, Zhenyan Nie, Zhihui Yuan, Jing Li,Xinghai Li

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

Yixian Liu, Yongji He,Xiaohui Qi,Xinghai Li, Yi Zhou,Yuanwei Chen,Zhenlei Wang,Li Zheng

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT（2024）

引用0浏览0WOS引用

Abstract LB157: Discovery of HP537, a Potent and Selective P300/cbp Inhibitor for the Treatment of Hematologic Malignancies

Jing Li, Zhilin Tu, Jian Peng, Lei Fan, Hua Yu, Fei Wang,Xinghai Li

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

Discovery of HC-4955, a Novel AR-V7-targeting PROTAC for the Treatment of Mcrpc

Jing Li, Zhilin Tu,Wu Du,Xi Xiang, Zeyu Wen,Yang You, Lijuan Zhao, Yin Chen,Chengcheng Yang, Hongwei Yuan,Xinghai Li

CANCER RESEARCHno. 7 (2024)

引用0浏览0引用

Abstract LB159: Discovery of HP560, a Novel BET Inhibitor for the Treatment of Myelofibrosis

Jing Li, Lei Fan,Hongwei Yuan, Yongxu Huo, Hua Yu, Fei Wang,Xinghai Li

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel

Soumen Saha,Samagya Banskota,Parisa Yousefpour,Jeffrey L. Schaal,Nikita Zakharov, Jianqiao Liu,Michael Dzuricky, Ziwei He,Stefan Roberts,Xinghai Li,Ashutosh Chilkoti

SMALL SCIENCE (2024)

引用0浏览0引用

Abstract LB175: Discovery of HP567, a Highly Potent, Brain-Penetrating, and H1047R-selective PI3Kα Inhibitor for the Treatment of Tumors Bearing H1047R Mutation

Jing Li,Lei Fan, Chengcheng Liu, Yao Luo, Xiaohui Chu,Hua Yu,Fei Wang,Xinghai Li

Cancer researchno. 7_Supplement (2024): LB175-LB175

引用0浏览0引用

Supplementary Table 1 from Brachytherapy Using Injectable Seeds That Are Self-Assembled from Genetically Encoded Polypeptides in Situ

Wenge Liu,Jonathan McDaniel,Xinghai Li,Daisuke Asai,Felipe Garcia Quiroz,Jeffery Schaal,Ji Sun Park,Michael Zalutsky,Ashutosh Chilkoti

crossref（2023）

引用0浏览0引用

Deutenzalutamide, an Oral Deuterated Androgen Receptor Inhibitor, Vs Placebo for Patients with Mcrpc Who Have Experienced Treatment Failure with Abiraterone and Docetaxel: Results of the HC-1119-04 Phase 3 Trial

Ding-Wei Ye,Chengyuan Gu, Lixin Hua,Ranlu Liu, Jun Li,Mingxing Qiu,Jianming Guo,Haiying Dong,Zhigang Ji, Hong Guo,Frank Perabo,Yuanwei Chen,Xinghai Li

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia

Ruilin Ding,Longxia Chen,Xinghai Li,Tengqiong Xiong,Hong Chen,Xiaojing Hu,Yun Li, Yi Zhou,Kezhi Liu,Jianhong Wu,Feng Jiang,Qing Peng

Clinical drug investigation（2023）

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn